Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 10 von 28):
LIXTE adds Lurie Cancer Center as a second site in its trial testing LB-100 and Dostarlimab for ovarian clear cell cancer.
Elixirgen reports the first-ever sustained telomere elongation in TBD patients using EXG-34217, with no safety concerns.
Lucid-MS, a neuroprotective MS drug by Quantum BioPharma, completes Phase 1 trial with no safety concerns.
Silo Pharma secures a new patent for SPC-15, an intranasal PTSD treatment, strengthening its intellectual property portfolio.
Renovaro and BioSymetrics merge to harness AI for biomarker discovery, precision medicine, and faster drug development.
Derm-Biome’s DB-007-5 surpasses top AD drugs in reducing itch and inflammation, showing promise for first-line treatment.
Rakovina and Variational AI strengthen their partnership to accelerate AI-powered cancer drug discovery.
IMUNON’s IMNN-101 vaccine demonstrates safety, strong immune response, and potential for future pandemics.
Humacyte launches Symvess, a bioengineered vessel designed to revolutionize emergency vascular repair and save limbs.
PDS Biotech’s immunotherapy Versamune® HPV shows promising clinical results in HPV-related cancers, per JAMA Oncology study.
Pharma leaders unite in Jordan for ARAB PHARMA MANUFACTURERS’ EXPO 2025, focusing on innovation and industry growth.
Hikma launches the first generic Mercaptopurine Oral Suspension in the US, gaining FDA approval and CGT exclusivity.
Nxera Pharma assigns APAC rights for cenerimod to Viatris, securing $10M and future milestone payments.
Cyclacel Pharmaceuticals names Datuk Dr. Doris Wong Sing Ee as CEO following a major ownership and leadership transition.
Myriad Genetics partners with Gabbi to integrate genetic testing with telehealth breast cancer risk assessment and specialist care.
Alumis unveils new data on A-005, a CNS-penetrant TYK2 inhibitor, with plans for a Phase 2 trial in multiple sclerosis.
Ocugen’s OCU410ST gains FDA backing for a Phase 2/3 trial, offering new hope for Stargardt disease patients.
Medicus Pharma begins a UAE clinical study for its non-invasive BCC treatment, strengthening its global development program.
It will bring together Europe’s top pharmaceutical outsourcing decision-makers, shining a spotlight on this rapidly growing industry.
NYBCe and Human Life CORD partner to advance MSC manufacturing, strengthening regenerative medicine supply worldwide.
AstraZeneca and Daiichi Sankyo’s Enhertu receives CHMP recommendation for EU approval in HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.
Novartis will showcase remibrutinib and Cosentyx® data at AAAAI/WAO and AAD 2025, supporting CSU regulatory filings.
Strand Life Sciences introduces the StrandOmics Portal to enhance rare disease diagnosis with faster genetic insights.
Valneva’s IXCHIQ® receives CHMP support for adolescent use, with EU approval expected in 60 days, boosting access.
Vincerx Pharma cancels reverse merger and explores strategic options, including M&A, asset sales, or winding down.
AbbVie and Gubra sign a licensing deal for GUB014295, a long-acting amylin analogue in Phase 1 trials for obesity.
Roche’s OUtMATCH study confirms Xolair’s effectiveness over OIT for food allergies, with fewer adverse events.
AstraZeneca’s Imfinzi gains EU backing for NSCLC, reducing recurrence risk by 32% in the AEGEAN trial.
Oryzon sets Phase III trial endpoints for vafidemstat in BPD, aligning with FDA standards and planning 2025 regulatory submission.
Australias TGA rejects lecanemab for early Alzheimers, disagreeing on safety for ApoE4 heterozygotes despite Eisais proposals
ACP-711 proves safe in Phase 1 study, prompting plans for further trials in elderly volunteers and higher doses.
Protagonist & Takeda’s rusfertide meets all endpoints in Phase 3 study, offering hope for polycythemia vera patients.
Seres Therapeutics receives FDA feedback on SER-155, planning next study to support allo-HSCT patients.
Pliant Therapeutics halts BEACON-IPF trial due to safety issues but sees early efficacy signs in pulmonary fibrosis treatment.
Genentech's TNKase gets FDA approval for acute ischemic stroke, providing a faster alternative to standard treatment.
Voyager's VY7523 anti-tau antibody demonstrates strong safety and tolerability in early trials, advancing to the next phase in Alzheimer's treatment research.
Zentalis will showcase azenosertib data at SGO 2025, highlighting clinical updates and biomarker insights in ovarian cancer.
Acurx's ibezapolstat shows reduced gut microbiome disruption in CDI treatment, surpassing VAN and MET in a study.
Ocugen’s gene therapies for vision loss receive EMA backing, showing promise in treating GA and Stargardt disease.
Amneal’s denosumab biosimilars move forward with FDA review, aiming to compete in the $5B osteoporosis drug market.
ANI Pharmaceuticals secures FDA approval for a prefilled Cortrophin® Gel syringe, enhancing convenience for patients.
Adverum launches ARTEMIS Phase 3 trial for Ixo-vec, a gene therapy designed to reduce injections for wet AMD patients.
Baxter introduces Voalte Linq, a voice-activated wearable that enhances hospital communication and workflow efficiency.
FDA accepts Roche’s sBLA for Gazyva in lupus nephritis, based on positive Phase III REGENCY study results.
Nelson Labs introduces Rapid Sterility Testing at three sites, cutting testing time while ensuring regulatory compliance.
Evotec receives $20M from Bristol Myers Squibb as their neuroscience collaboration reaches a key milestone.
J&J names Darren Snellgrove VP of Investor Relations as Jessica Moore becomes CFO of Innovative Medicine.
New research confirms NXP900 boosts osimertinib’s effect in EGFR-mutated NSCLC, reducing resistance and tumour growth.
Tiziana submits IND for Phase 2 ALS trial of intranasal foralumab, aiming to improve treatment for neurodegenerative diseases.
Enzene’s Pune sites receive EU GMP certification, supporting commercial biologics production with advanced manufacturing tech.
Syner-G & Sequoia appoint Chris Erickson as COO, leveraging his 25+ years of experience to drive operational growth.
Aenova upgrades Bad Aibling site with €20M investment, enhancing blister and effervescent packaging capabilities.
Jazz acquires Chimerix for $935M, adding glioma treatment dordaviprone to its rare oncology pipeline.
Tenax increases TNX-103 trial enrollment and prepares for global Phase 3 study, aiming to advance PH-HFpEF treatment.
Certara appoints Adrian McKemey to lead drug development solutions, enhancing biosimulation and R&D strategy.
Vaxart's oral norovirus vaccine shows strong immune responses in older adults, published in Science Translational Medicine.
Circio's circVec platform shows 70x RNA durability vs. mRNA, opening new possibilities for gene and cell therapies.
Lisata and GATC Health deepen partnership to develop a non-opioid treatment for opioid use disorder, targeting Phase 1 trials in early 2026.
Oryzon publishes a PMS study, paving the way for vafidemstat trials in precision psychiatry and rare CNS disorders.
Acadia’s DAFFODIL™ study affirms DAYBUE’s safety in Rett syndrome patients aged 2–4, reinforcing FDA-approved use.
Parexel appoints Jeff Bernstein, Partner at Goldman Sachs Asset Management, to its Board of Directors, bringing extensive healthcare investment and leadership experience.
aTyr Pharma’s Phase 3 EFZO-FIT™ study on efzofitimod advances smoothly after a positive safety assessment.
Ourvita expands in Asia with Braveiy acquisition, enhancing global manufacturing and innovation in health and wellness.
Sun Pharma expands oncology portfolio with Checkpoint acquisition, bringing FDA-approved UNLOXCYT to global markets.
OMLYCLO® becomes the first FDA-approved interchangeable biosimilar to XOLAIR®, expanding treatment access for allergy patients.
Novo Nordisk’s CagriSema shows major weight loss benefits for obesity and diabetes, with FDA filing expected in 2026.
VIVUS’ QSYMIA® gets UAE approval, expanding treatment options for obesity in adults and children aged 12 and older.
Dr. Mark Frohlich joins Rigel’s Board, adding expertise in oncology and immunotherapy to its leadership team.
Pittcon 2025 in Boston featured groundbreaking lab innovations, expert insights, and global scientific collaboration.
4D Molecular Therapeutics advances to Phase 3 with its 4D-150 gene therapy for wet AMD, aiming to reduce treatment burden and preserve vision.
Biodexa gains FDA guidance for its Phase 3 eRapa trial in FAP, setting the stage for patient enrollment next quarter.
Tevogen Bio patents an AI-powered T-cell vaccine designed to target entire viral genomes and enhance immune response.
CervoMed’s neflamapimod shows promising results in the 16-week extension phase of Phase 2b trial for dementia with Lewy bodies.
LIXTE announces findings on LB-100 activation, identifying a biomarker that may predict patient response to treatment.
Tonix receives MCDC funding for TNX-801, mpox and smallpox vaccine, supporting market analysis and commercialization.
The 9th Biologics Festival & 15th Vaccine World Summit 2025 drive innovation in India's biopharma industry.
Phase 3 results show vepdegestrant improves progression-free survival in ER+/HER2- metastatic breast cancer patients.
Olivia Brown joins Ipsen to drive global neurotoxins strategy, overseeing therapeutic and aesthetic growth initiatives.
Roche and Zealand Pharma collaborate to develop petrelintide, aiming to transform obesity care with innovative therapies.
Madrigal welcomes biotech leader Jackie Fouse to its board as the company expands MASH treatment efforts.
Kane Biotech marks a three-year deal with Best Buy Medical to expand revyve™ Antimicrobial Wound Gel in Canada.
Merck launches a $1B Durham vaccine plant, integrating AI, 3D printing, and digital twin tech for efficiency.
Cognizant and Boehringer launch a unified Veeva-powered platform, enhancing drug development and regulatory workflows.
aTyr Pharma’s efzofitimod study reveals its role in reducing lung inflammation and fibrosis via NRP2 targeting.
Portage Biotech resumes patient enrollment in the final dose escalation stage of its PORT-6 Phase 1b trial after a funding delay.
FDA expands ILUVIEN’s label to include chronic non-infectious uveitis, improving treatment options for patients.
Gradalis' study in Scientific Reports highlights exome sequencing to enhance cancer immunotherapy targeting.
Dyne’s DYNE-251 demonstrates sustained improvement in Duchenne patients, advancing toward potential FDA approval in 2026.
Roche unveils long-term data at MDA 2025: Evrysdi shows sustained motor function stabilization in SMA, while Elevidys demonstrates promising results in DMD treatment.
TRYVIO is now fully released from REMS, expanding access to patients with difficult-to-control hypertension.
ASIA LABEX 2025 unites experts, exhibitors, and innovators to showcase the latest lab advancements in Chandigarh.
Argent BioPharma reports positive Phase IIb results for CimetrA®, highlighting its safety, faster recovery, and anti-inflammatory potential.
AstraZeneca's acquisition of EsoBiotec aims to transform cell therapy, making treatments faster and more accessible.
BridgeBio Pharma welcomes Thomas Trimarchi as President & CFO while Brian Stephenson transitions to a consulting role.
Eneboparatide meets key endpoints in a Phase III trial, showing promise for chronic hypoparathyroidism treatment.
Pliant’s PLN-101095, combined with pembrolizumab, shows anti-tumor activity in ICI-refractory cancers in Phase 1 trial.
Telix’s Illuccix® secures ANVISA approval, bringing advanced PSMA-PET imaging to prostate cancer patients in Brazil.
AstraZeneca’s Imfinzi secures EU approval, offering a new immunotherapy option for limited-stage small cell lung cancer.
Perspective Therapeutics doses first patient in a new cohort studying [212Pb]VMT01 with nivolumab for melanoma treatment.
Greenwich LifeSciences’ FLAMINGO-01 trial confirms GLSI-100’s strong safety profile, with no serious adverse events.
Capricor’s HOPE-2 trial data shows deramiocel preserves muscle function, slowing Duchenne muscular dystrophy progression.
Genmab’s Rina-S achieves a 55.6% response rate in ovarian cancer, with Phase 3 trials underway for further evaluation.
AstraZeneca licenses ALT-B4 from Alteogen to develop subcutaneous cancer treatments, improving patient convenience.
SIGA adds General Jack Keane to its board, enhancing biodefense strategy with his national security expertise.
Whitehawk Therapeutics unveils its new name and vision, accelerating next-gen ADCs for cancer treatment.
Chugai introduces LUNSUMIO, a bispecific antibody, as a new treatment for relapsed follicular lymphoma in Japan.
FDA accepts BLA for AVT03, a proposed biosimilar to Prolia® and Xgeva®, developed by Alvotech and Dr. Reddy’s.
Allogenica receives €2.5M to scale its universal CAR-T therapy, offering a cost-effective solution for blood cancer patients.
ANI Pharmaceuticals introduces Nitazoxanide Tablets, offering a cost-effective alternative for patients nationwide.
Auron Therapeutics names Glenn Goddard as CFO, strengthening financial strategy as it advances groundbreaking therapies.
Todd Baumgartner joins Applied Therapeutics as Chief Regulatory Officer to lead global regulatory strategy for rare disease therapies.
Join the London Biotechnology Show 2025 at ExCeL London for cutting-edge insights, networking, and industry advancements.
Recognizing top pharma quality teams for innovation, reliability, and industry leadership. Nominate today!
Join industry leaders in Mumbai for Pharma GMP & Quality 2025, focusing on compliance, AI, and manufacturing excellence.
Merck unveils breakthrough research on PAH & cholesterol management at ACC.25, shaping the future of heart health.
Join top EHS leaders at the 2nd EHS for Biopharma East Summit 2025 to explore safety, sustainability, and compliance trends.
Sanofi strengthens its immunology pipeline by acquiring DR-0201, a novel B-cell depletion therapy for autoimmune diseases.
Alvotech expands R&D with Xbrane’s acquisition, strengthening biosimilar development and establishing a Swedish presence.
Infinitopes welcomes biotech leaders Dan Menichella & Jo Brewer to its board as it moves its cancer vaccine ITOP1 into clinical trials.
Novartis' gene therapy OAV101 IT improves motor function in SMA patients, marking a major step forward in treatment.
Dr. Igor Matushansky joins Immuneering to lead clinical trials for cutting-edge cancer therapies, including IMM-1-104.
Plus Therapeutics secures FDA conditional acceptance for REYOBIQ™, its lead radiotherapeutic for CNS cancers, boosting brand recognition.
CARBIOS names Isabelle Parize as Chairwoman and Vincent Kamel as CEO, following Philippe Pouletty’s resignation.
FDA approves Telix’s Gozellix®, improving PSMA-PET imaging access for prostate cancer patients across the U.S.
Harbour BioMed and AstraZeneca team up on next-gen antibody therapies, with a $105M investment and $4.7B in milestone payments.
CStone applies for EMA approval of sugemalimab in stage III NSCLC, backed by strong GEMSTONE-301 Phase III trial results.
Everest’s EVM14, an mRNA cancer vaccine for NSCLC and HNSCC, gets FDA IND clearance, marking a key milestone.
Junshi Biosciences’ Toripalimab-Bevacizumab Combo Gains NMPA Approval for First-Line Advanced Liver Cancer Treatment
Newronika’s AlphaDBS receives CE Mark, bringing adaptive deep brain stimulation to Parkinson’s patients in Europe.
DBV's Viaskin peanut patch for 4–7-year-olds advances toward FDA approval with VITESSE data, accelerating its launch.
Novo Nordisk secures global rights (ex. China) for UBT251, a next-gen obesity & diabetes drug, in a $2B deal with TUL.
Elicio Therapeutics names Dr. Preetam Shah as CFO, strengthening its leadership in cancer immunotherapy innovation.
PharmAla partners with a U.S. logistics firm to enhance MDMA clinical trial distribution and mitigate import risks.
The FDA is reviewing tolebrutinib to slow MS-related disability, with a decision expected by September 2025.
Tempero Bio starts a Phase 2 trial for TMP-301, an mGluR5 NAM for alcohol use disorder, under a deal with Nxera.
New data from Onconetix’s Proclarix® confirms high accuracy in prostate cancer detection, reducing false positives.
Alumis teams up with Kaken to bring ESK-001, a next-gen TYK2 inhibitor, to Japanese patients with immune disorders.
AstraZeneca’s Tagrisso shows strong results at ELCC 2025, extending survival and quality of life for lung cancer patients.
Hikma strengthens its US portfolio with Cisatracurium Besylate Injection, supporting anesthesia and critical care.
TFS HealthScience appoints Miriam Martin as VP of Business Development, strengthening strategic growth and clinical innovation.
Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal worth up to $1.97 billion.
Charles River and Valo Health’s AI-powered Logica® identifies a potential lupus treatment, accelerating drug discovery.
Elutia’s antibiotic-eluting bioenvelope eradicates bacteria, showing promise in preventing CIED infections.
David Banko joins Tevogen Bio as Global Head of Government Affairs, driving patient access and commercialization strategies.
Sanofi’s mRNA chlamydia vaccine moves forward with FDA fast track, aiming to combat rising global infection rates.
Jane Healy joins Photocure as GM EMEA, bringing decades of expertise to drive growth in uro-oncology across Europe.
Alvotech, Kashiv, and Advanz Pharma announce MHRA acceptance of AVT23, a biosimilar to Xolair® for asthma and nasal polyps.
Shane Olwill joins Asgard Therapeutics as CDO to lead the development of AT-108, a breakthrough cancer immunotherapy.
Avalo Therapeutics welcomes Michael Heffernan as Chairman to drive growth and pipeline expansion in immune-mediated diseases.
Intellia’s NTLA-2001 earns FDA RMAT designation, accelerating its development for transthyretin amyloidosis with cardiomyopathy.
Join biopharma experts in San Francisco for key insights on biotech, biomanufacturing, and future innovations.
Pittcon 2027 brings global scientists back to Pittsburgh, marking 60 years since its last event in the city.
Ajay Royan rejoins Invivyd’s Board to support breakthrough monoclonal antibody treatments for high-risk patients.
Chugai’s Evrysdi tablet offers SMA patients a more convenient treatment option with easier storage and administration.
Alvotech welcomes Dr. Balaji Prasad as Chief Strategy Officer to advance biosimilar innovation and global market expansion.
BridgeBio receives Japanese approval for Beyonttra (acoramidis) to treat ATTR-CM, with Alexion leading commercialization and a $30M milestone payment.
LIXTE Biotechnology updates on LB-100 trials for ovarian and colorectal cancer, progressing with GSK and Roche collaborations.
CPHI Americas 2025 gathers pharma leaders in Philadelphia for three days of networking, innovation, and collaboration.
Merck’s subcutaneous pembrolizumab meets key endpoints in Phase 3 trial, showing promise for lung cancer treatment.
PacBio names Jim Gibson as CFO, tapping into his leadership experience from Tesla, Apple, and Netflix to fuel growth.
Regeneron and Sanofi’s Dupixent receives approval in Japan for COPD, offering new hope for patients with uncontrolled disease.
IASO Bio secures NDA approval in Macau for Equecabtagene Autoleucel, a breakthrough for relapsed multiple myeloma.
Chugai and IFReC uncover FOXP3’s regulatory network, opening doors to innovative autoimmune disease treatments.
Elutia teams up with Advantus to offer EluPro™, an FDA-cleared antibiotic-eluting BioEnvelope, through GPO networks.
Genmab’s TIVDAK gets Japan’s first ADC approval for advanced cervical cancer, cutting death risk by 30% in trials.
FDA flags manufacturing and impurity issues in CARDAMYST review; Milestone to work on resubmission for approval.
Langhua Pharmaceutical passes its fourth FDA inspection, boosting its global CDMO services for small-molecule drug development.
CDMO Live 2025 unites pharma leaders in Rotterdam to discuss outsourcing, innovation, and strategic partnerships.
Novartis promotes Karen Hale to Chief Legal & Compliance Officer as Klaus Moosmayer steps down in April 2025.
AstraZeneca’s Calquence receives CHMP recommendation, showing a 27% risk reduction in MCL progression or death.
Valneva applies for UK approval to extend IXCHIQ® use to adolescents, following EMA’s positive opinion.
AAVantgarde and TIGEM's study in Science Advances highlights a novel AAV-based gene therapy for Stargardt’s disease.
IDEAYA’s darovasertib gets FDA Breakthrough Therapy status for neoadjuvant uveal melanoma treatment, advancing to Phase 3.
Kenan Thompson shares his GERD journey with Phathom to help others find relief and spark conversations on treatment.
Merck’s WINREVAIR™ delivers a 76% risk reduction in PAH mortality & hospitalization in a groundbreaking clinical trial.
TransCon CNP, a weekly treatment for achondroplasia, shows promise in growth, muscle function, and leg straightening.
Nxera Pharma appoints Kiyoshi Kaneko as CCO and promotes Mariko Nakafuji to CLO to support global expansion.
TEV-'749 receives strong patient and provider satisfaction in the SOLARIS trial, presented at SIRS 2025.
LIXTE and NKI launch a pre-clinical study to explore LB-100’s ability to eliminate early cancer-linked cells.
TIVDAK earns EU approval, becoming the first ADC for recurrent or metastatic cervical cancer, improving survival rates.
Telix initiates the ZOLAR trial, exploring TLX300-CDx as a theranostic solution for metastatic soft tissue sarcoma.
TONIX ONE™ integrates telehealth, e-prescriptions, and symptom tracking to simplify migraine management.
The EU grants approval for Valneva’s IXCHIQ® vaccine in adolescents, expanding protection against chikungunya.
Amneal and Shilpa debut BORUZU™, a ready-to-use bortezomib injection for multiple myeloma and lymphoma, simplifying prep.
Apellis’ EMPAVELI® for rare kidney diseases gets FDA Priority Review; intense Phase 3 results support approval bid.
Inventiva enrolls 1,419 patients in Phase 3 trial for lanifibranor, a potential MASH treatment; results expected in H2 2026.
Join experts at Pharma Sterile & Injectables 2025 to explore innovations, regulations, and best practices in manufacturing.
Rilzabrutinib receives FDA orphan drug status for wAIHA & IgG4-RD, marking progress in rare disease treatment.
Novo Nordisk restructures its executive team as Camilla Sylvest steps down, appointing new leaders in key strategic roles.
Roche’s Phase III MUSETTE trial confirms OCREVUS 600 mg as optimal for MS, showing record-low relapse rates.
Algorae welcomes Vishal Shah as CCO, leveraging his 20+ years of pharma leadership to fuel growth and innovation.
Anne Whitaker joins Telix as Non-Executive Director, bringing global pharma and Nasdaq governance expertise.
Globus Medical completes Nevro acquisition, unlocking a $2.5B chronic pain and neuromodulation market.
Argent BioPharma gains approval for CannEpil™ in Germany, expanding access for patients with refractory epilepsy.
ONTOFORCE launches DISQOVER to streamline access and integration of Parkinson’s disease research data, accelerating insights and scientific collaboration.
GSK partners with ABL Bio for £2B+ deal to develop neurodegenerative therapies using Grabody-B BBB platform.
LIfT BioSciences names Mark Exley CSO to steer clinical launch of its neutrophil-based cancer immunotherapy.
Telix names Dr. Paul Schaffer CTO, boosting its radiopharma leadership with expertise in isotope technology.
SkyCell partners with Microsoft to embed AI in Teams, improving pharma logistics with real-time insights and alerts.
India’s pharma sector gains profit from Trump’s tariff relief on medicines, boosting exports and bilateral trade ties.